CN1568196A - 免疫功能受损病人的营养治疗 - Google Patents

免疫功能受损病人的营养治疗 Download PDF

Info

Publication number
CN1568196A
CN1568196A CNA028199790A CN02819979A CN1568196A CN 1568196 A CN1568196 A CN 1568196A CN A028199790 A CNA028199790 A CN A028199790A CN 02819979 A CN02819979 A CN 02819979A CN 1568196 A CN1568196 A CN 1568196A
Authority
CN
China
Prior art keywords
sod
nutritional supplement
component
carnitine
hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028199790A
Other languages
English (en)
Chinese (zh)
Inventor
卡尔·格尔马诺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Biotechnologies Inc
Original Assignee
Millennium Biotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Biotechnologies Inc filed Critical Millennium Biotechnologies Inc
Publication of CN1568196A publication Critical patent/CN1568196A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/446—Superoxide dismutase (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
CNA028199790A 2001-08-10 2002-08-09 免疫功能受损病人的营养治疗 Pending CN1568196A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/927,174 US6503506B1 (en) 2001-08-10 2001-08-10 Nutrient therapy for immuno-compromised patients
US09/927,174 2001-08-10

Publications (1)

Publication Number Publication Date
CN1568196A true CN1568196A (zh) 2005-01-19

Family

ID=25454328

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028199790A Pending CN1568196A (zh) 2001-08-10 2002-08-09 免疫功能受损病人的营养治疗

Country Status (9)

Country Link
US (1) US6503506B1 (https=)
EP (1) EP1432436A4 (https=)
JP (1) JP2005501061A (https=)
CN (1) CN1568196A (https=)
AP (1) AP2004002994A0 (https=)
CA (1) CA2457624A1 (https=)
EA (1) EA006439B1 (https=)
OA (1) OA12649A (https=)
WO (1) WO2003013438A2 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105709212A (zh) * 2016-01-29 2016-06-29 周瑞华 一种免疫平衡调节剂及其制备方法和应用
CN110664824A (zh) * 2019-08-09 2020-01-10 北京佳博泰和健康科技有限公司 一种营养支持剂及其制备方法和用途
CN111820330A (zh) * 2020-07-17 2020-10-27 禹城保立康生物饲料有限公司 一种提高哺乳仔猪发育的母猪饲料
CN113142581A (zh) * 2010-12-23 2021-07-23 阿马曾提斯公司 用于改善线粒体功能的组合物和方法

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6616942B1 (en) 1999-03-29 2003-09-09 Soft Gel Technologies, Inc. Coenzyme Q10 formulation and process methodology for soft gel capsules manufacturing
FR2822704B1 (fr) * 2001-03-29 2005-02-18 Chiesi Sa Sels de cetoacides et d'acides amines gastroresistants et leur utilisation pour la preparation de medicaments
US6503506B1 (en) * 2001-08-10 2003-01-07 Millenium Biotechnologies, Inc. Nutrient therapy for immuno-compromised patients
US20080089877A1 (en) * 2003-08-14 2008-04-17 Udell Ronald G Super Absorption Coenzyme Q10
US8124072B2 (en) 2003-09-29 2012-02-28 Soft Gel Technologies, Inc. Solubilized CoQ-10
US8105583B2 (en) * 2003-09-29 2012-01-31 Soft Gel Technologies, Inc. Solubilized CoQ-10
US7169385B2 (en) * 2003-09-29 2007-01-30 Ronald G. Udell Solubilized CoQ-10 and carnitine
ITTO20030789A1 (it) 2003-10-07 2005-04-08 Professional Dietetics Srl Composizione a base di amino acidi per il trattamento
WO2005039318A1 (en) * 2003-10-16 2005-05-06 Nestec S.A. Nutritional composition against side effects of chemotherapy of radiotherapy
ES2809302T3 (es) 2004-01-22 2021-03-03 Univ Miami Formulaciones de coenzima Q10 para tratar tumores sólidos mediante administración intravenosa
JP2007519678A (ja) * 2004-01-28 2007-07-19 ネステク ソシエテ アノニム 皮膚状態を改良しそして皮膚病を予防するための栄養組成物
US20050209170A1 (en) * 2004-03-18 2005-09-22 Takemoto Arnold C Breast health preparations
WO2005089412A2 (en) * 2004-03-17 2005-09-29 Takemoto Arnold C Tissue detoxification and health supplements and methods of making and using them
JP2005336176A (ja) * 2004-04-28 2005-12-08 Tanabe Seiyaku Co Ltd 肉体疲労改善剤
EP1600061B1 (en) * 2004-05-25 2010-05-12 Cognis IP Management GmbH Oral and/or topical compositions
US20050265990A1 (en) * 2004-06-01 2005-12-01 Shawn Talbott Treatments and nutritional supplements for assisting post-exercise recovery
WO2006003927A1 (ja) * 2004-06-30 2006-01-12 Atsuo Sekiyama 非炎症性ストレス応答の指標剤およびその利用
KR100584891B1 (ko) 2004-08-13 2006-05-30 (주)씨스팜 경구용 슈퍼옥사이드 디스뮤타제 제제인, 캔털루프 멜론추출물과 글리아딘 결합물을 숙취해소에 사용하는 방법
US7284385B2 (en) * 2004-09-16 2007-10-23 Hess Spencer W Pre-dried air reactivation for diesel fuel heated dessicant reactivator
JP5040060B2 (ja) * 2004-10-14 2012-10-03 大正製薬株式会社 メチオニン配合内服液剤
US20060147550A1 (en) * 2004-12-30 2006-07-06 Gorsek Wayne F Immune system enhancement and stimulation formulation
US20070114476A1 (en) * 2005-11-04 2007-05-24 Williams Christopher P Low radiocarbon nucleotide and amino acid dietary supplements
RU2414897C2 (ru) * 2005-11-30 2011-03-27 Нестек С.А. Способы лечения потери мышечной массы
WO2007077995A1 (ja) * 2006-01-05 2007-07-12 Kyowa Hakko Kogyo Co., Ltd. 筋肉増量剤
GB0603975D0 (en) * 2006-03-01 2006-04-05 Etren Methods and agents for reducing oxidative stress
WO2007105024A1 (en) * 2006-03-15 2007-09-20 Isocell Pharma S.A. Pharmaceutical compositions comprising sods and prolamine based peptide fragments
FR2899065B1 (fr) * 2006-03-29 2008-07-18 Alain Dreyer Brevets Et Dev So Sod micro encapsulee et adsorbee sur support mineral et vegetal destinee a l'alimentation animale
DE102006046960A1 (de) * 2006-10-04 2008-04-10 Euro Allianz Pharma Gmbh Gesundheitsfördernde Nahrungsmittelzusammensetzung
US20080119386A1 (en) * 2006-11-22 2008-05-22 Carl Germano Nutritional formula for athletes' recovery
US8343541B2 (en) 2007-03-15 2013-01-01 Soft Gel Technologies, Inc. Ubiquinol and alpha lipoic acid compositions
EP2158462A4 (en) 2007-05-03 2010-05-05 Radiocarb Genetics Inc FOOD SUPPLEMENTS WITH LITTLE RADIO CARBON AND MANUFACTURING METHOD THEREFOR
KR20150064233A (ko) * 2007-09-27 2015-06-10 바이오테라, 인크. 상부 호흡기 감염 증상 및 심리적 웰빙의 베타-글루칸 처리
WO2009099444A1 (en) * 2008-02-08 2009-08-13 Millennium Biotechnologies, Inc. Nutritional formula for athletes' recovery
AU2009233785B2 (en) 2008-04-11 2015-08-20 Berg Llc Methods and use of inducing apoptosis in cancer cells
US8865733B2 (en) * 2008-11-06 2014-10-21 Altman Enterprises, LLC Medication and treatment for disease
AU2010247800A1 (en) 2009-05-11 2011-12-15 Berg Llc Methods for the diagnosis of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
EP2311449A1 (de) * 2009-10-14 2011-04-20 NÖM Aktiengesellschaft Oral verabreichbare nahrungsergänzende Zusammensetzung enthaltend Carnitin
WO2012097061A1 (en) * 2011-01-13 2012-07-19 Abbott Laboratories Nutritional compositions and methods for improving skeletal muscle protein metabolism
EP2665473A4 (en) 2011-01-18 2014-08-20 Equine Nutriceuticals Llc FOOD SUPPLEMENT FOR HORSES
CA2832324C (en) 2011-04-04 2022-03-15 Berg Llc Methods of treating central nervous system tumors
SG10201903112WA (en) 2013-04-08 2019-05-30 Berg Llc Treatment of cancer using coenzyme q10 combination therapies
KR102370843B1 (ko) 2013-09-04 2022-03-04 버그 엘엘씨 코엔자임 q10의 연속주입에 의한 암치료 방법
WO2017087576A1 (en) 2015-11-16 2017-05-26 Berg Llc Methods of treatment of temozolomide-resistant glioma using coenzyme q10
RU2656544C1 (ru) * 2017-07-07 2018-06-05 Общество с ограниченной ответственностью "Академия-Т" Функциональный продукт питания для коррекции психофизиологического состояния и нейромышечной передачи у спортсменов
CA3109188A1 (en) * 2018-08-10 2020-02-13 Maine Natural Health Company, Inc. Comestible compositions for promoting atp synthesis
GB202308224D0 (en) 2023-06-01 2023-07-19 Amazentis Sa Formulation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5456924A (en) * 1988-12-23 1995-10-10 Immunotec Research Corporation Ltd. Method of treatment of HIV-seropositive individuals with dietary whey proteins
IT1258491B (it) * 1992-09-24 1996-02-26 Sigma Tau Ind Farmaceuti Impiego di l-carnitina e acil l-carnitine nel trattamento di pazienti affetti da aids e sindromi correlate e di pazienti asintomatici hiv- sieropositivi.
FR2729296B1 (fr) 1995-01-12 1997-03-28 Europlanaire Compositions pharmaceutiques comprenant une superoxyde dismutase
US5817329A (en) * 1997-02-28 1998-10-06 Gardiner; Paul T. Nutritional supplement for increased muscle size and strength for body builders
US6503506B1 (en) * 2001-08-10 2003-01-07 Millenium Biotechnologies, Inc. Nutrient therapy for immuno-compromised patients

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113142581A (zh) * 2010-12-23 2021-07-23 阿马曾提斯公司 用于改善线粒体功能的组合物和方法
CN113142581B (zh) * 2010-12-23 2025-07-22 阿马曾提斯公司 用于改善线粒体功能的组合物和方法
CN105709212A (zh) * 2016-01-29 2016-06-29 周瑞华 一种免疫平衡调节剂及其制备方法和应用
CN110664824A (zh) * 2019-08-09 2020-01-10 北京佳博泰和健康科技有限公司 一种营养支持剂及其制备方法和用途
CN111820330A (zh) * 2020-07-17 2020-10-27 禹城保立康生物饲料有限公司 一种提高哺乳仔猪发育的母猪饲料

Also Published As

Publication number Publication date
OA12649A (en) 2006-06-16
US6503506B1 (en) 2003-01-07
EA200400291A1 (ru) 2004-08-26
CA2457624A1 (en) 2003-02-20
EA006439B1 (ru) 2005-12-29
AP2004002994A0 (en) 2004-03-31
EP1432436A4 (en) 2005-02-09
WO2003013438A2 (en) 2003-02-20
EP1432436A2 (en) 2004-06-30
WO2003013438A3 (en) 2003-06-19
JP2005501061A (ja) 2005-01-13

Similar Documents

Publication Publication Date Title
CN1568196A (zh) 免疫功能受损病人的营养治疗
Cruzat et al. Effects of supplementation with free glutamine and the dipeptide alanyl‐glutamine on parameters of muscle damage and inflammation in rats submitted to prolonged exercise
CN1753625A (zh) 用含亮氨酸的制剂刺激体内蛋白质的产生
JP7434155B2 (ja) オートファジーの誘導のためにオートファジー誘導因子と高タンパク質との組み合わせを使用する組成物及び方法
CN103945711B (zh) 对抗肌萎缩和少肌症的乳清蛋白胶束
JP2005514342A (ja) 栄養補助作用および栄養強化作用を有する薬用−食調製物
US9956255B1 (en) Method to reduce body weight, fat accumulation and adipocyte size using Parabacteroides goldsteinii
CN1901920A (zh) 含有氨基葡糖的食物组合物
CN1217667C (zh) 一种能够提高认知能力的食品
CN1674795A (zh) 治疗或预防哺乳动物遭受代谢作用压力时的分解代谢或刺激性合成代谢的方法及组合物
ES2351701T3 (es) USO DE ß-CRIPTOXANTINA.
CN1921842A (zh) 包含泛酸或其衍生物的组合物及其刺激食欲的应用
CN1299690C (zh) 用于提高心血管功能的组合物
US20120309716A1 (en) Motor Function Improver
Batiha et al. Deciphering the immunoboosting potential of macro and micronutrients in COVID support therapy
WO2013170189A1 (en) Combination of beta - hydroxy - beta - methylbutyrate and beta - alanine for increasing muscle blood flow
ES2743955T3 (es) Composiciones que comprenden cinamaldehído y zinc y métodos para utilizar tales composiciones
EP3174548B1 (en) Marine peptides and fish nucleotides, compositions and uses thereof for reducing blood glucose
JP2024545404A (ja) 動物において健康上の効果を提供するためのアミノ酸ブレンドを使用する組成物及び方法
KR20050034568A (ko) 무산소 상태에서 순간적인 임팩트 파워를 증대 시키는필수 아미노산중 분지사슬아미노산을 이용한 건강기능식품
JP5922862B2 (ja) ミトコンドリア機能向上剤
CN1655810A (zh) 高尿酸血症治疗或预防用组合物
US20120178799A1 (en) Energy beverage with creatine and caffeine combination
RU2614881C1 (ru) Комплекс биологически активных веществ, защищающих спортсменов от перетренированности
HK1073261A (en) Nutrient therapy for immuno-compromised patients

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1073261

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1073261

Country of ref document: HK